Clinical Trial

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Study acronym: SURPASS-EARLY
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2022-06-22; most recent amendment 2025-12-05.
Status change: Recruiting → Active, Not Recruiting 2024-01-22
Status change: Not Yet Recruiting → Recruiting 2022-08-17
Trial Details
NCT Number NCT05433584
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes
Enrollment 780 participants
Start Date 2022-08-01
Primary Completion 2025-10-21 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-12